Erlotinib Tablet, Film Coated
Product Images NDC 72485-217

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Erlotinib (NDC 72485-217). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clin-1 (Cur 1)

Kaplan-Meier curves depicting investigator-assessed progression-free survival (PFS) probability over time in months for two groups: Chemotherapy and Erlotinib. The graph shows decreasing survival probability with increasing duration of progression-free survival, accompanied by a table of patient numbers at risk for each group at various time points shown below the x-axis.*

FDA Label Image

Clin-2 (Cur 2)

Kaplan-Meier curves showing overall survival probability over time (months) for patients in Study 3, comparing treatment groups: Erlotinib and Placebo. The graph plots survival probability on the vertical axis against overall survival in months on the horizontal axis, with patient counts at risk listed for each group at various time points.*

FDA Label Image

Cli-3 (Cur 3)

A Kaplan-Meier curve chart showing overall survival probability over time in months for patients treated with Erlotinib versus placebo. The chart includes survival probability on the vertical axis and overall survival in months on the horizontal axis, with a table displaying the number of patients at risk for each treatment group at various time points.*

FDA Label Image

Clin-4 (Cur 4)

A Kaplan-Meier survival curve graph titled 'Kaplan-Meier Curves for Overall Survival: 100 mg Cohort in Study 5' comparing survival probability over time (months) between Placebo and Erlotinib groups. The x-axis represents overall survival in months (0 to 36), and the y-axis represents survival probability (0 to 1.0). Below the graph is a table listing the number of patients at risk at different time points for each group.*

FDA Label Image

Er-des (Des 1)

Chemical structure diagram of Erlotinib hydrochloride, showing its molecular framework with aromatic rings, nitrogen atoms, and ether groups.*

FDA Label Image

Erlt-25 (Erl 25)

Erlotinib Tablets 25 mg film-coated oral tablets packaging label. The label indicates 30 tablets per package, manufactured by Shilpa Medicare Limited, India, and distributed by Armas Pharmaceuticals Inc., USA. Storage instructions, usual dosage advisory, barcode, and the Armas Pharmaceuticals logo are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.